Recent advancements in microtubule targeting agents for breast cancer: design strategies and pharmacological insights

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Chemotherapeutic resistance and recurrence remain significant challenges in breast cancer management.
• Microtubule-targeting agents are crucial for breast cancer therapy, but traditional drugs face limitations like toxicity and resistance.
• Novel agents targeting tubulin offer potential solutions against resistant cancer cells.

Purpose of the Study:

• To review the design strategies, structure-activity relationships, and pharmacology of novel microtubule-targeting agents.
• To explore the potential of multi-targeting and dual-targeting ligands in combination therapy.
• To encourage the development of next-generation, selective, and safer antimitotic agents for breast cancer.

Main Methods:

• Literature review of recent advancements in microtubule-targeting agents for breast cancer.
• Analysis of structure-activity relationships for novel scaffolds and molecular hybrids.
• Discussion of pharmacological properties and potential therapeutic applications.

Main Results:

• Novel scaffolds and molecular hybrids demonstrate potent activity against resistant breast cancer cells.
• Targeting colchicine or taxane sites on tubulin is a viable strategy.
• Multi-targeting and dual-targeting ligands exhibit promising combinatory effects.

Conclusions:

• New classes of microtubule-targeting agents offer improved efficacy and safety profiles.
• Further research into these novel agents can lead to better breast cancer treatment outcomes.
• Development of selective and safer antimitotic drugs is essential for managing resistant breast cancer.